Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Severe infusion reactions to fabry enzyme replacement therapy: rechallenge after tracheostomy.

Nicholls K, Bleasel K, Becker G.

JIMD Rep. 2012;5:109-12. doi: 10.1007/8904_2011_106. Epub 2011 Dec 11.

2.

Enzyme replacement therapy with agalsidase alfa in children with Fabry disease.

Ramaswami U, Wendt S, Pintos-Morell G, Parini R, Whybra C, Leon Leal JA, Santus F, Beck M.

Acta Paediatr. 2007 Jan;96(1):122-7.

PMID:
17187618
3.

Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme.

Bodensteiner D, Scott CR, Sims KB, Shepherd GM, Cintron RD, Germain DP.

Genet Med. 2008 May;10(5):353-8. doi: 10.1097/GIM.0b013e318170f868.

PMID:
18496035
4.

Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.

Thofehrn S, Netto C, Cecchin C, Burin M, Matte U, Brustolin S, Nunes AC, Coelho J, Tsao M, Jardim L, Giugliani R, Barros EJ.

Ren Fail. 2009;31(9):773-8. doi: 10.3109/08860220903150296.

PMID:
19925283
6.

Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey.

Ramaswami U, Parini R, Pintos-Morell G, Kalkum G, Kampmann C, Beck M; FOS Investigators.

Clin Genet. 2012 May;81(5):485-90. doi: 10.1111/j.1399-0004.2011.01671.x. Epub 2011 Apr 25.

PMID:
21457233
7.

Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis.

Alegra T, Vairo F, de Souza MV, Krug BC, Schwartz IV.

Genet Mol Biol. 2012 Dec;35(4 (suppl)):947-54. Epub 2012 Dec 18.

8.

Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.

Mignani R, Feriozzi S, Pisani A, Cioni A, Comotti C, Cossu M, Foschi A, Giudicissi A, Gotti E, Lozupone VA, Marchini F, Martinelli F, Bianco F, Panichi V, Procaccini DA, Ragazzoni E, Serra A, Soliani F, Spinelli L, Torti G, Veroux M, Cianciaruso B, Cagnoli L.

Nephrol Dial Transplant. 2008 May;23(5):1628-35. Epub 2007 Dec 5.

9.

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting.

Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO.

Nephrol Dial Transplant. 2006 Feb;21(2):345-54. Epub 2005 Oct 4.

10.

Fabry disease, enzyme replacement therapy and the significance of antibody responses.

Deegan PB.

J Inherit Metab Dis. 2012 Mar;35(2):227-43. doi: 10.1007/s10545-011-9400-y. Epub 2011 Oct 25. Review.

PMID:
22037707
11.

Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.

Pisani A, Spinelli L, Visciano B, Capuano I, Sabbatini M, Riccio E, Messalli G, Imbriaco M.

JIMD Rep. 2013;9:41-8. doi: 10.1007/8904_2012_177. Epub 2012 Oct 21.

12.

Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience.

Ghali J, Nicholls K, Denaro C, Sillence D, Chapman I, Goldblatt J, Thomas M, Fletcher J; Australian State Fabry Disease Treatment Centres.

JIMD Rep. 2012;3:33-43. doi: 10.1007/8904_2011_44. Epub 2011 Sep 15.

13.
14.

Fabry disease: overall effects of agalsidase alfa treatment.

Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A.

Eur J Clin Invest. 2004 Dec;34(12):838-44.

PMID:
15606727
15.

Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).

Hoffmann B, Garcia de Lorenzo A, Mehta A, Beck M, Widmer U, Ricci R; FOS European Investigators.

J Med Genet. 2005 Mar;42(3):247-52.

16.

Hearing improvement in patients with Fabry disease treated with agalsidase alfa.

Hajioff D, Goodwin S, Quiney R, Zuckerman J, MacDermot KD, Mehta A.

Acta Paediatr Suppl. 2003 Dec;92(443):28-30; discussion 27.

PMID:
14989462
17.

Improvement of sympathetic skin responses under enzyme replacement therapy in Fabry disease.

Jardim LB, Gomes I, Netto CB, Nora DB, Matte US, Pereira F, Burin MG, Kalakun L, Giugliani R, Becker J.

J Inherit Metab Dis. 2006 Oct;29(5):653-9. Epub 2006 Jul 27.

PMID:
16972173
18.

Progressive renal failure despite long-term biweekly enzyme replacement therapy in a patient with Fabry disease secondary to a new α-galactosidase mutation of Leu311Arg (L311R).

Suzuki K, Miura N, Kitagawa W, Suzuki S, Komatsuda A, Nishikawa K, Watanabe D, Imai H.

Clin Exp Nephrol. 2011 Dec;15(6):916-20. doi: 10.1007/s10157-011-0486-1. Epub 2011 Jul 15. Review.

PMID:
21755431
19.

Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease.

Zamorano J, Serra V, Pérez de Isla L, Feltes G, Calli A, Barbado FJ, Torras J, Hernandez S, Herrera J, Herrero JA, Pintos G.

Eur J Echocardiogr. 2011 Sep;12(9):671-7. doi: 10.1093/ejechocard/jer109. Epub 2011 Aug 2.

20.

Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.

van Breemen MJ, Rombach SM, Dekker N, Poorthuis BJ, Linthorst GE, Zwinderman AH, Breunig F, Wanner C, Aerts JM, Hollak CE.

Biochim Biophys Acta. 2011 Jan;1812(1):70-6. doi: 10.1016/j.bbadis.2010.09.007. Epub 2010 Sep 17.

Items per page

Supplemental Content

Write to the Help Desk